Copyright
©The Author(s) 2018.
World J Clin Oncol. Nov 10, 2018; 9(7): 140-147
Published online Nov 10, 2018. doi: 10.5306/wjco.v9.i7.140
Published online Nov 10, 2018. doi: 10.5306/wjco.v9.i7.140
Table 1 Karnofsky performance status categories suggested for interconversion to Eastern Cooperative Oncology Group performance status in the literature
Author, year | n and patients, assessments | Setting | KPS categories | ECOG |
AJCC[34], 1977 | - | - | 90-100 | 0 |
70-80 | 1 | |||
50-60 | 2 | |||
30-40 | 3 | |||
10-20 | 4 | |||
Minna et al[20], 1985 | - | - | 100 | 0 |
80-90 | 1 | |||
60-70 | 2 | |||
40-50 | 3 | |||
20-30 | 4 | |||
Buccheri et al[10], 1996 | 536 (1656) | Subjects with lung cancer visiting a cancer clinic of a tertiary care centre | 80-100 | 0-1 |
60-70 | 2 | |||
10-50 | 3-4 | |||
Ma et al[19], 2010 | 1385 (1385) | Subjects visiting an oncology palliative care clinic, or admitted to an acute cancer palliative care unit | 100 | 0 |
80-90 | 1 | |||
60-70 | 2 | |||
40-50 | 3 | |||
10-30 | 4 | |||
de Kock et al[18], 2013 | 955 (674) | Subjects with advanced life-limiting illnesses (cancer and non-cancer) in acute care and community settings | 60-100 | 1 |
50 | 2 | |||
30-40 | 3 | |||
10-20 | 4 | |||
Current study | 1501 (5844) | Subjects with lung cancer visiting a cancer clinic of a tertiary care center | 100 | 0 |
80-90 | 1 | |||
70 | 2 | |||
50-60 | 3 | |||
10-40 | 4 |
Table 2 Baseline characteristics of the study population n (%)
Characteristic | Total, n = 1501 |
Age in yr | 58.4 (10.8) |
Males | 1236 (82.3) |
Smokers | 1155 (76.9) |
Body mass index in kg/m2 | 20.2 (4.2) |
Histopathology | |
NSCLC: Squamous | 553 (36.8) |
NSCLC: Adeno | 514 (34.2) |
NSCLC: Undifferentiated | 87 (5.8) |
NSCLC: Other | 42 (2.8) |
SCLC | 305 (20.3) |
NSCLC/SCLC stage1 | |
I and II | 44 (2.9) |
IIIA | 193 (12.9) |
IIIB | 426 (28.4) |
IV | 767 (51.1) |
SCLC stage | |
Limited disease | 145 (9.7) |
Extensive disease | 160 (10.7) |
Baseline performance status | |
KPS | 77.6 (14.4) |
ECOG PS | 1.5 (1) |
Table 3 Correlation between Karnofsky performance status and Eastern Cooperative Oncology Group performance status
Visit number | Number of assessments | Spearman’s correlation coefficient1 |
1 | 1426 | -0.727 |
2 | 1099 | -0.890 |
3 | 957 | -0.876 |
4 | 823 | -0.863 |
5 | 602 | -0.858 |
6 | 464 | -0.867 |
7 | 270 | -0.901 |
8 | 129 | -0.854 |
9 | 54 | -0.773 |
10 | 20 | -0.972 |
Overall | 5844 | -0.840 |
Table 4 Comparison of the performance of various suggested Karnofsky performance status categories (for interconversion to the Eastern Cooperative Oncology Group performance status scale) in the current cohort
Author, year | Hit rate1 | κw1 |
AJCC et al[34], 1977 | 43.60% | 0.376 (0.363-0.389) P < 0.0001 |
Minna et al[20], 1985 | 75.20% | 0.701 (0.687-0.714) P < 0.0001 |
Buccheri et al[10], 1996 | 83.20% | 0.695 (0.679-0.711) P < 0.0001 |
Ma et al[19], 2010 | 75.20% | 0.701 (0.687-0.714) P < 0.0001 |
de Kock et al[18], 2013 | 43.20% | 0.079 (0.068-0.090) P < 0.0001 |
Current study | 78.10% | 0.749 (0.736-0.762) P < 0.0001 |
- Citation: Prasad KT, Kaur H, Muthu V, Aggarwal AN, Behera D, Singh N. Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients. World J Clin Oncol 2018; 9(7): 140-147
- URL: https://www.wjgnet.com/2218-4333/full/v9/i7/140.htm
- DOI: https://dx.doi.org/10.5306/wjco.v9.i7.140